Evidence map›Paper›PMID 27347066›Full record

ArticleExperimental and therapeutic medicine2016

Attenuation effect of Abnormal Savda Munziq on liver and heart toxicity caused by chemotherapy in mice.

Ainiwaer Aikemu, Nurmuhamat Amat, Abdiryim Yusup, Lianlian Shan, Xinwei Qi, Halmurat Upur

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Anticancer Potential of Valencia Peanut (Foods (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ainiwaer AikemuDepartment of Drug Analysis, Faculty of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China.
Nurmuhamat AmatFaculty of Traditional Uighur Medicine, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China.
Abdiryim YusupFaculty of Traditional Uighur Medicine, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China.
Lianlian ShanDepartment of Drug Analysis, Faculty of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China.
Xinwei QiMedical Research Center, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China.
Halmurat UpurFaculty of Traditional Uighur Medicine, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China.
Xinjiang Medical University · CNFirst Affiliated Hospital of Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abnormal Savda Munziq (ASMq), an Uighur medicine formula commonly used in the treatment of cancer, has been speculated to possess antioxidative and antiproliferative effects, and to regulate immune activity. The present study was designed to systematically elucidate the toxicity-reducing activity of ASMq in mice undergoing combination chemotherapy with doxorubicin and 5-fluorouracil (5-FU). The mice were divided into normal (saline, 10 ml/kg) and doxorubicin + 5-FU groups (doxorubicin, 2.5 mg/kg; 5-FU, 10 mg/kg on alternate days). In addition, three groups received different doses of ASMq (2, 4 and 8 g/kg), in addition to doxorubicin (2.5 mg/kg) and 5-FU (10 mg/kg) treatment on alternate days. The histology of the heart and liver, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) activity, malondialdehyde (MDA) concentrations in heart homogenate, and various biochemical parameters of the liver were evaluated. Compared with the normal control group, ASMq dose-dependently improved a number of variables, including body weight, liver index, transaminase and total protein, and partially normalized liver and cardiac pathology. ASMq restored activities of defense antioxidant enzymes SOD and GSH-Px towards normal levels, and decreased MDA concentration in dose-dependent manner. These results demonstrated that ASMq provides significant protection against doxorubicin + 5-FU combination induced hepatotoxicity and cardiotoxicity. Further studies are required to determine the effects of ASMq against doxorubicin + 5-FU-induced toxicity during chemotherapy

Indexed as

abnormal Savda Munziqanthraquinoneantioxidant effectchemotherapytoxicity

Identifiers

PMID27347066
PMCPMC4906975
OpenAlexW2396406758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.